Introduction
============

Chronic obstructive pulmonary disease (COPD) and bronchial asthma are common respiratory diseases that are caused by chronic or excessive inflammation of the airways.

Chronic inflammation of the airways in these diseases is mediated by substantially distinct immunological reactions, with different patterns of inflammatory cells and mediators, particularly in patients with mild to moderate diseases. The inflammatory process in COPD is characterized by increases in macrophages, neutrophils and CD8^+^ T cells ([@b26-copd-3-619]; [@b40-copd-3-619]; [@b33-copd-3-619]), as well as important mediators such as interleukin 8 (IL-8) and tumor necrosis factor-alpha (TNF-α) ([@b19-copd-3-619]). On the other hand, the inflammatory process in asthma is characterized by increased eosinophils, mast cells and type-2 helper T (Th2) cells, which produce IL-4, -5 and -13 ([@b15-copd-3-619]).

These immunological differences between COPD and asthma are considered to be associated with differences in the efficacy of inhaled corticosteroid (ICS) therapy as well as airway structural changes (ie, airway remodeling) between these diseases. Among the components of airway remodeling, microvascular alterations have been increasingly noted in both diseases. ICS is known to be the most effective therapy available for treatment of asthma, particularly in patients with mild to moderate disease ([@b10-copd-3-619]). Indeed, numerous studies showing the effects of ICS on bronchial biopsy and bronchoalveolar lavage samples in patients with asthma have demonstrated that the increased numbers of CD4^+^ T cells, eosinophils and mast cells and increased vascularity seen in this disease are substantially reduced by ICS ([@b47-copd-3-619]; [@b11-copd-3-619]; [@b17-copd-3-619]). In contrast, patients with COPD respond poorly to ICS treatment. It is generally assumed that neutrophils are less sensitive to corticosteroids than are eosinophils and T cells ([@b67-copd-3-619]). These differences in the responsiveness of activated inflammatory cells help to explain why ICS treatment has been more beneficial for patients with asthma than COPD. Furthermore, these differences in corticosteroid responsiveness between COPD and asthma can also be used for differential diagnosis.

However, it has now become evident that these immunological profiles of both diseases are altered during progression from mild to severe diseases. In severe COPD, the number of macrophages, activated neutrophils, natural killer lymphocytes in the subepithelium are further increased in comparison with subjects with mild to moderate diseases ([@b21-copd-3-619]). Furthermore, bronchial inflammation in severe COPD is characterized by lower numbers of CD3^+^ and CD8^+^ T cells in comparison with subjects with mild to moderate diseases ([@b22-copd-3-619]). These findings show a shift of inflammatory profiles involved in severe diseases. On the other hand, some of the common features of COPD and asthma, including increased numbers of neutrophils, increased amounts of TNF-α and poor responses to corticosteroids, are seen in patients with both severe cases ([@b37-copd-3-619]; [@b42-copd-3-619]; [@b12-copd-3-619]; [@b53-copd-3-619]; [@b8-copd-3-619], [@b9-copd-3-619]). This not only makes differential diagnosis complicated but also has important implications for the development of therapeutic strategies for patients with severe COPD or asthma.

In this review, we focus on the role of microvessels in the development of airway obstructive diseases, including COPD and asthma, and discuss how the immunological features of patients with severe diseases affect the microvascular alterations in both diseases. Notably, this article highlights the possible crucial involvement of TNF-α and CXC chemokines, rather than vascular endothelial growth factor (VEGF), in the microvascular alterations seen in COPD and asthma, particularly in severe cases.

VEGF and microvascular alterations in COPD and asthma
=====================================================

Vascular regulation by VEGF
---------------------------

VEGF was originally identified as a vascular permeability factor based on its ability to cause tissue edema ([@b69-copd-3-619]). Subsequently, VEGF has been widely recognized as one of the most potent angiogenic factors, mediating the growth of new vessels from preexisting ones ([@b63-copd-3-619]). The process of angiogenesis is a complex and highly orchestrated series of multiple events, including proliferation, migration, survival and tube formation of vascular endothelial cells. VEGF has several isoforms that are produced by alternative splicing of a single VEGF gene ([@b25-copd-3-619]) and act via their specific receptors, VEGFR1/Flt-1 and/or VEGFR2/KDR/Flk-1, on vascular endothelial cells ([@b77-copd-3-619]).

VEGF in COPD
------------

Both functional (increased microvascular permeability, edema and inflammatory cell recruitment) and structural (angiogenesis) changes in the airway microvessels are seen in chronic airway inflammatory conditions. Although microvascular alterations in asthma are well documented, as described below, those in COPD have not been fully elucidated yet. An early report indicated that the alveolar septa in emphysema appear to be remarkably thin and almost avascular ([@b51-copd-3-619]). Later, Abman and Voelkel et al demonstrated that lung blood vessels actively promote normal alveolar development and contribute to the maintenance of alveolar structure ([@b39-copd-3-619]; [@b45-copd-3-619]; [@b3-copd-3-619]). These studies indicated that a reduction in the blood supply of the microvessels might induce the destruction of alveolar septa. Indeed, VEGF concentration in induced sputum was significantly reduced in emphysema ([@b43-copd-3-619]). Similarly, VEGFR2 expression was also decreased in total lung extracts of emphysema patients ([@b45-copd-3-619]). On the contrary, VEGF concentration in induced sputum was significantly elevated in chronic bronchitis patients, although those levels were lower than those in asthmatic patients. Similar to the pattern seen in asthmatics, chronic bronchitis patients show an inverse correlation between the concentration of VEGF and the forced expiratory volume in one second (FEV~1~). In contrast, the concentration of VEGF correlated positively with FEV~1~ in emphysema patients, probably due to VEGF-mediated maintenance of the alveolar structure. Thus, the VEGF level in the lung is considered to explain the pathologies in COPD.

VEGF in asthma
--------------

To date, numerous studies have shown that VEGF is critically involved in the microvascular alterations observed in asthma. Exaggerated levels of VEGF have been detected in asthmatic airways compared with in the airways in normal control subjects ([@b35-copd-3-619], [@b36-copd-3-619]; [@b6-copd-3-619]; [@b44-copd-3-619]; [@b5-copd-3-619]; [@b18-copd-3-619]). VEGF levels in the airways show a positive correlation with airway inflammation ([@b50-copd-3-619]) and correlate inversely with lung function ([@b5-copd-3-619]), suggesting that VEGF plays important roles in the pathogenesis of asthma. In a murine model of bronchial asthma, lung-specific and inducible over-expression of VEGF was shown to enhance not only angiogenesis, but also Th2 inflammation and hyperresponsiveness of the airways ([@b49-copd-3-619]). Importantly, the biological effects of overexpressed VEGF, such as angiogenesis, were reversed by cessation of the transgenic VEGF elaboration in that murine model, suggesting that the effects of VEGF on the development of airway hypervascularity are dependent upon its expression level. In humans, ICS treatment was found to effectively reduce VEGF production in the airways, thereby reducing the submucosal vascularity ([@b6-copd-3-619]; [@b17-copd-3-619], [@b18-copd-3-619]; [@b2-copd-3-619]; [@b24-copd-3-619]). However, it should be noted that these studies were restricted to cases of mild to moderate asthma. Therefore, any role of VEGF in severe refractory asthma remains unclear.

CXC chemokines and microvascular alterations in COPD and asthma
===============================================================

Vascular regulation by CXC chemokines
-------------------------------------

Chemokines convey specificity to the leukocyte recruitment cascade by inducing leukocyte subtypes to adhere to endothelium and activate so as to play an essential role in the inflammatory process. Chemokines are divided into two major subfamilies, CXC and CC, based on the position of the first two conserved cysteine residues: the two cysteines are separated by a non-conserved amino acid in CXC chemokines, whereas they are adjacent in CC chemokines ([@b78-copd-3-619]). CXC chemokines are further subdivided into ELR and non-ELR types based on the presence or absence of a glutamic acid, leucine and arginine sequence adjacent and N-terminal to the CXC motif. Members of the CXC chemokines with an ELR-motif include growth-related oncogene alpha (Gro-α)/CXC ligand 1 (CXCL1), Gro-β/CXCL2, Gro-γ/CXCL3, epithelial neutrophil activating peptide 78 (ENA78)/CXCL5, granulocyte chemotactic protein 2 (GCP2)/CXCL6 and IL-8/CXCL8. These molecules act as major chemoattractants for neutrophils. In contrast, members of the CXC chemokines without an ELR-motif include monokine induced by IFN-γ (MIG)/CXCL9, interferon (IFN)-inducible protein 10 (IP-10)/CXCL10 and IFN-inducible T cell alpha chemoattractant (I-TAC)/CXCL11, and these chemokines act as chemoattractants for Th1 cells.

These two subtypes of CXC chemokines show disparate properties regarding angiogenesis and can be divided into an angiogenic ELR-positive type and an angiostatic ELR-negative type. The angiogenic activity of ELR-positive CXC chemokines, such as IL-8, is mediated via their common receptor, CXC chemokine receptor 2 (CXCR2), which is expressed on microvascular endothelial cells ([@b4-copd-3-619]; [@b32-copd-3-619]). These chemokines are thus referred to as "CXCR2 chemokines" throughout this manuscript. In contrast, the angiostatic activity of ELR-negative CXC chemokines, such as IP-10, is mediated via their common receptor, CXCR3, which is also expressed on microvascular endothelial cells ([@b48-copd-3-619]). These chemokines are thus referred to as "CXCR3 chemokines" throughout this manuscript.

The process of angiogenesis is known to be regulated by a complex interaction of activators and inhibitors, and inappropriate production of these factors may cause aberrant angiogenesis. As a matter of fact, a recent report indicated the importance of the CXC chemokine-mediated angiogenic/angiostatic balance in bleomycin-induced pulmonary fibrosis. The study clearly showed that a CXCR3 chemokine, I-TAC, inhibits IL-8-mediated angiogenesis ([@b14-copd-3-619]).

CXC chemokines in COPD
----------------------

In contrast to asthma, CD4^+^ T cells that accumulate in the airways of patients with COPD are mainly Th1 cells producing IFN-γ ([@b52-copd-3-619]; [@b60-copd-3-619]). CXCR3 chemokines such as IP-10 are induced by IFN-γ from a variety of cell types ([@b66-copd-3-619]; [@b29-copd-3-619]), including endothelial cells ([@b54-copd-3-619]; [@b55-copd-3-619]). Furthermore, studies of peripheral lung lymphocytes from cigarette smokers with emphysema indicated that their CD4^+^ T cells are not only polarized to the Th1 phenotype, but also secreted more CXCR3 chemokines compared to those in the group without emphysema ([@b27-copd-3-619]). Immunoreactivity for IP-10 was detected in the airway epithelium ([@b65-copd-3-619]) and smooth muscle ([@b29-copd-3-619]) of COPD patients but not in normal control subjects. Furthermore, in response to IP-10, but not IFN-γ, lung macrophages secreted matrix metalloproteinase-12 (MMP12), a potent elastin-degrading enzyme that causes tissue destruction and has been linked to emphysema ([@b27-copd-3-619]). Thus, CXCR3 chemokines are considered to be involved in the pathogenesis of COPD, particularly in emphysema.

As described above, these chemokines also act as potent anti-angiogenic factors. In addition to reduction of VEGF, overproduction of CXCR3 chemokines may promote avascularity of the emphysema lung ([@b43-copd-3-619]). However, it is evident that IL-8, a proangiogenic CXCR2 chemokine, is also predominant in patients with COPD ([@b61-copd-3-619]). TNF-α appears to play a role in the pathogenesis of COPD ([@b19-copd-3-619]), and the levels of TNF-α are further upregulated in severe COPD patients ([@b28-copd-3-619]) and patients experiencing acute COPD exacerbation ([@b1-copd-3-619]). Human airway smooth muscle cells ([@b29-copd-3-619]), epithelial cells ([@b66-copd-3-619]) and microvascular endothelial cells ([@b55-copd-3-619]) treated simultaneously with IFN-γ and TNF-α demonstrated robust increases in the production of CXCR3 chemokines compared with cells treated with either stimulus alone. These findings strongly suggest that overproduction of CXCR3 chemokines induced by the combination of IFN-γ and TNF-α is more involved in the pathogenesis of severe COPD, at least in part through their excess anti-angiogenic activity, than is CXCR2 chemokine-mediated angiogenic activity. Importantly, proliferation and tube formation by human lung microvascular endothelial cells was almost completely inhibited in the co-presence of IFN-γ and TNF-α in vitro, even in the presence of sufficient amounts of recombinant VEGF ([@b55-copd-3-619]). This observation is also fully compatible with the pathological findings of avascularity in emphysema. Thus, CXCR3 chemokines might be involved in the aberrant vascularity, which is responsible for destruction of the alveolar septa, observed in patients with severe emphysema, as well as their chemotactic properties.

As described above, levels of CXCR2 ligands, such as IL-8 and ENA78/CXCL5 are elevated in bronchoalveolar lavage fluid of COPD patients ([@b61-copd-3-619]). These chemokines recruit and activate neutrophils via their receptor CXCR2 expressed on neutrophils. Therefore, small molecule inhibitors of CXCR2 such as SB225002 are likely to be useful for attenuating CXCR2 ligands-mediated neutrophilic inflammation in the COPD airway ([@b31-copd-3-619]; [@b7-copd-3-619]). However, considering especially for the CXC chemokines-mediated angiogenic-angiostatic balance in the airway, CXCR2 antagonists are likely to be more useful for severe asthma than for severe COPD, as discussed below.

CXC chemokines in asthma
------------------------

Although VEGF-mediated airway hypervascularity in patients with asthma is responsive to corticosteroid treatment ([@b6-copd-3-619]; [@b17-copd-3-619], [@b18-copd-3-619]; [@b2-copd-3-619]; [@b24-copd-3-619]), several clinical studies have also demonstrated that airway hypervascularity is seen in fatal ([@b76-copd-3-619]) and severe corticosteroid-dependent asthma ([@b75-copd-3-619]) and even in patients treated with ICS for more than 5 years ([@b73-copd-3-619]). Of note, structural abnormalities of airway remodeling are present in children with severe asthma. Tillie-Leblond et al studied bronchial biopsies from severe asthma with persistent symptoms in two groups of children with or without persistent airflow obstructive pattern. Persistent obstructive pattern was defined as a FEV~1~ less than 80% of the predicted value after a course of systemic corticosteroids and no significant improvement after bronchodilator. They demonstrated that an increase in the density of the vascular network was more pronounced in children with persistent airflow obstruction than in children without persistent airflow obstruction ([@b74-copd-3-619]). These observations indicate that airway hypervascularity in severe asthma is poorly responsive to corticosteroid treatment and is clinically involved in lung function. Therefore, another possible explanation of the cause besides VEGF might be the presence of hypervascularity in severely asthmatic airways. Recently, we have shown that, only in the presence of TNF-α, IL-4/13 and IFN-γ reciprocally regulate angiogenesis by human lung microvascular endothelial cells in vitro through autocrine synthesis of CXCR2 and CXCR3 chemokines, respectively ([@b55-copd-3-619]). It should be noted that CXCR2 chemokine-induced angiogenesis is independent of VEGF. These results highlight the importance of TNF-α for VEGF-independent/CXCR2 chemokine family-dependent angiogenesis. While both IL-8 and TNF-α are abundant in the severely asthmatic airways ([@b37-copd-3-619]; [@b12-copd-3-619]; [@b53-copd-3-619]; [@b70-copd-3-619]), airway hypervascularity in severe asthma might be primarily due to TNF-α and CXCR2 chemokines rather than mediation by VEGF. Furthermore, corticosteroid therapies would offer little hope for improving TNF-α/CXCR2 chemokine-associated angiogenesis, because corticosteroid has scant effect on TNF-α-induced CXCR2 chemokine production by human lung microvascular endothelial cells ([@b56-copd-3-619]). Therefore, CXCR2 antagonists are likely to be useful for attenuating TNF-α/CXCR2 chemokines-mediated hypervascularity in addition to blocking chemokine-induced neutrophil chemotaxis and activation ([@b8-copd-3-619]) in patients with severe asthma, which are characterized by elevated levels of TNF-α and neutrophilic inflammation.

Corticosteroid actions in pulmonary microvascular endothelial cells
===================================================================

In the context discussed above, TNF-α-associated CXC chemokines appear to play critical roles in vascular alterations in both COPD and asthma, especially in severe cases. In addition to these structural alterations, TNF-α also plays crucial roles in vascular functions by regulating leukocyte recruitment into local inflamed tissues ([@b46-copd-3-619]), which is an important step in the development of acute and chronic inflammatory responses ([@b16-copd-3-619]). This recruitment is a dynamic process requiring interactions between leukocytes and the vascular endothelium. To that end, TNF-α induces endothelial cell expression of various molecules, including intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), that are essential for those interactions ([@b20-copd-3-619]). Recently, we demonstrated that TNF-α-induced expressions of ICAM-1 and VCAM-1 on human lung micro-vascular endothelial cells were further enhanced by corticosteroid treatment ([@b56-copd-3-619]). Correspondingly, adhesion of eosinophils and neutrophils to these cells was also enhanced by corticosteroid treatment, suggesting that instead of inhibiting the recruitment of inflammatory cells into local inflamed tissues, ICS therapies actually promote their adhesion, probably via upregulation of cell-surface expression of ICAM-1 and VCAM-1 on the endothelium. Indeed, in severe asthma, a highly significant correlation was found between the total number of vessels and the vessels expressing ICAM-1 in biopsy specimens ([@b75-copd-3-619]), which supports the hypothesis that ICS therapies are not effective in reducing ICAM-1 expression on the endothelium. While TNF-α-induced IP-10 expression in microvascular endothelial cells is further enhanced by corticosteroid treatment ([@b56-copd-3-619]), ICS therapies might not be effective in curing the avascularity observed in emphysema patients. Together, ICS therapies offer little expectation for improving TNF-α-mediated pulmonary microvascular alterations, including CXCR2 chemokine-mediated angiogenesis, CXCR3 chemokine-mediated avascularity and inflammatory cell recruitment. Moreover, these microvascular alterations mediated by TNF-α might be clinically associated with the development of COPD and also asthma.

TNF-α is a major therapeutic target in chronic inflammatory diseases including rheumatoid arthritis and Crohn's diseases ([@b23-copd-3-619]). Recently, clinical trials of anti-TNF-therapy have demonstrated good improvement in lung function and airway hyperresponsiveness in severe refractory asthma ([@b37-copd-3-619]; [@b12-copd-3-619]). Thus, it is now recognized that anti-TNF therapies are likely to become an important treatment option for patients with refractory asthma ([@b34-copd-3-619]). The effectiveness of anti-TNF therapies in such patients may be at least partly due to the prevention of TNF-α-activated vascular inflammation. However, a clinical study has demonstrated that subjects with moderate to severe COPD did not benefit from treatment with anti-TNF therapy ([@b62-copd-3-619]). It is currently unclear why the anti-TNF therapy is more effective for severe asthma than for severe COPD. Although further studies are needed to elucidate the pathological roles in TNF-α of severe COPD and asthma, respectively, differences in increased number of blood vessels, which are major targets of TNF-α, in the airway between these diseases (ie, avascularity in severe COPD and hypervascularity in severe asthma) may reflect to the efficacy of anti-TNF therapy.

Possibility of microvessel-targeted treatment options in COPD and asthma
========================================================================

The impact of corticosteroids on pulmonary microvascular endothelial cells is apparently distinct from that on other airway structural cells, including epithelial cells, smooth muscle cells and fibroblasts, in which TNF-α-induced expressions of chemokines and cellular adhesion molecules are significantly downregulated by corticosteroid treatment ([@b71-copd-3-619]; [@b38-copd-3-619]; [@b58-copd-3-619]; [@b56-copd-3-619]). Increased amounts of TNF-α and poor responses to corticosteroids are common features observed in both COPD and severe asthma. Therefore, TNF-α-mediated responses of pulmonary microvessels, such as inflammatory cell recruitment into inflamed tissues and inflammatory chemokine expression, may at least partially explain the corticosteroid refractoriness in these diseases. In this context, as a new therapeutic strategy for patients with severe COPD or asthma, the near future holds the possibility of direct microvessel-targeted topical treatment options.

ICAM-1 is a potential candidate molecule for targeted treatment of patients with severe COPD or asthma. Although there have not been any clinical trials of anti-ICAM-1 therapy for patients with severe COPD or asthma, in a rat model of extrinsic asthma, administration of monoclonal antibody to ICAM-1 significantly attenuated both the early and late responses of bronchial asthma ([@b57-copd-3-619]). In ICAM-1-deficient mice, significant inhibition of lung tissue eosinophil recruitment ([@b13-copd-3-619]) and airway hyper-reactivity ([@b30-copd-3-619]) were observed after allergen challenge. ICAM-1 is expressed not only on the inflamed endothelium but also on inflamed fibroblasts and epithelium in the airways. Respiratory viruses are a major cause of exacerbations of both COPD and asthma, and the most prevalent viruses detected during exacerbations are the rhinoviruses ([@b59-copd-3-619]; [@b41-copd-3-619]; [@b68-copd-3-619]; [@b64-copd-3-619]). Since ICAM-1 is a major receptor for rhinovirus ([@b72-copd-3-619]), anti-ICAM-1 therapy might be effective in preventing rhinovirus-induced exacerbations of these diseases in addition to attenuating inflammatory cell recruitment into local inflamed tissues.

Alternatively, as described above, CXCR3 and CXCR2 might be potential candidate molecules for targeted treatment of patients with severe COPD and asthma, respectively. Anti-CXCR3 therapy might bring about improvement of CXCR3 chemokine-induced avascularity in addition to attenuating Th1 inflammation in emphysema patients. In contrast, anti-CXCR2 therapy might lead to improvement of CXCR2 chemokine-induced hypervascularity in addition to neutrophilic inflammation in severe asthmatics.

Conclusions
===========

COPD and asthma are chronic inflammatory diseases of the airways, and characteristic structural alterations in the airways are observed in each disease, including microvascular alterations. These microvascular alterations caused by chronic inflammation appear to be clinically involved in both diseases. Although the type of inflammation is quite different between COPD and asthma, especially in patients with mild to moderate disease, increased amounts of TNF-α, neutrophilic inflammation and poor responses to corticosteroids are the common features in patients with severe COPD or asthma.

[Figure 1](#f1-copd-3-619){ref-type="fig"} presents an overview of microvascular alterations in pulmonary inflammatory diseases discussed in this review. In COPD, VEGF concentration in chronic bronchitis patients is significantly elevated, although those levels are lower than those in asthmatic patients. However, increased numbers of microvessels (ie, angiogenesis) in the airway of COPD patients have not been established. Some COPD patients with emphysema show rather reduced production of VEGF, resulting in the destruction of alveolar septa. In contrast, in mild to moderate asthma, increased production of VEGF in the airway is critically involved in angiogenesis, but such VEGF-mediated angiogeneis in the asthmatic airway is effectively reversed by corticosteroid treatment. In patients with severe COPD or severe asthma, TNF-α, which is a pleiotropic proinflammatory cytokine that exerts its biological effects mainly by acting on the vascular endothelium, is abundant in the airway. Only in the presence of TNF-α, IL-4/13 and IFN-γ reciprocally regulate angiogenic-angiostatic balance through autocrine synthesis of CXCR2 and CXCR3 chemokines, respectively. Corticosteroid therapies would offer little hope for improving TNF-α/CXCR2 chemokine-associated angiogenesis, and thus hypervascularity in severe asthma might be primarily due to TNF-α and CXCR2 chemokines rather than mediation by VEGF. On the other hand, TNF-α-associated overproductions of CXCR3 chemokines in severe emphysema might be involved in the avascularity in alveolar septa, in addition to reduction of VEGF. Moreover, TNF-α also plays crucial roles directly in vascular functions by regulating leukocyte recruitment into local inflamed tissues, but corticosteroid therapies would enhance these inflammatory responses on the microvessels rather than inhibit them.

Thus, TNF-α and CXC chemokines can be surmised to be critically associated with microvascular alterations in patients with severe pulmonary inflammatory diseases. Further studies are required to examine whether CXCR3/CXCR2 chemokines play roles in the attenuation and development of pulmonary angiogenesis in patients with severe COPD and asthma, respectively. Nevertheless, there is the possibility of microvessel-targeted treatment options in the near future for these patients, whereas ICS therapies offer little expectation for improvement of these microvascular alterations mediated by TNF-α and CXC chemokines.
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